New hope for tough GvHD: pomalidomide shows promise in small trial
NCT ID NCT01688466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD) that didn't improve with standard treatments. GvHD can happen after a stem cell transplant when the donor cells attack the recipient's body. Participants took pomalidomide capsules daily for up to 6 months, and researchers checked if the disease got better or worse. The goal was to see if the drug is safe and can help control this condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Can a cancer drug tame graft-versus-host disease when steroids fail?
- Scientists map immune battlefield in chronic GVHD tissue
- New antibody may offer safer shield against transplant complications